ArticleNeurology(R) neuroimmunology & neuroinflammation2016
Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Current Perspectives on JC Polyomavirus Transmission and Associated Diseases: Implications for Prevention in Risk Populations.Viruses · 2026Review
- JC Polyomavirus Infection: A Narrative Review.Infectious diseases and therapy · 2025Review
- Natalizumab-associated progressive multifocal leukoencephalopathy.Frontiers in neurology · 2025Review
- Harnessing the Power of IL-7 to Boost T Cell Immunity in Experimental and Clinical Immunotherapies.Immune network · 2024Review
- Dietary Marine Oils Selectively Decrease Obesogenic Diet-Derived Carbonylation in Proteins Involved in ATP Homeostasis and Glutamate Metabolism in the Rat Cerebellum.Antioxidants (Basel, Switzerland) · 2024Article
- Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy.Frontiers in immunology · 2024Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
- A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy.PloS one · 2023Article
- Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report.Therapeutic advances in hematology · 2023Article
- Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab.HemaSphere · 2022Article
- Innovative therapeutic concepts of progressive multifocal leukoencephalopathy.Journal of neurology · 2022Review
- Advances in Treatment of Progressive Multifocal Leukoencephalopathy.Annals of neurology · 2021Review
- BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study.The Lancet. Neurology · 2021Article
- Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosis.Therapeutic advances in neurological disorders · 2021Article
- Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.Nature reviews. Neurology · 2021Review
- Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient.Blood advances · 2020Article
- Progressive Behavior Changes and Brain Lesions in a Lung Transplant Recipient.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Global HIV neurology: a comprehensive review.AIDS (London, England) · 2019Review
- Neurologic Complications of Human Immunodeficiency Virus Infection.Continuum (Minneapolis, Minn.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo describe the compassionate use of interleukin-7 (IL-7) for treatment of progressive multifocal leukoencephalopathy (PML) in the setting of idiopathic CD8+ greater than CD4+ lymphocytopenia.
methodsA 66-year-old HIV-seronegative man presented with progressive language dysfunction. MRI showed hyperintense lesions in the left hemispheric white matter with mild contrast enhancement. A brain biopsy performed 4 months after symptom onset established the diagnosis of PML. The patient had profound lymphocytopenia with absolute lymphocyte count (ALC) at 168 cells/μL, 87 CD4+ T cells/μL, and 7 CD8+ T cells/μL. There was no evidence of hematologic malignancy or rheumatologic disease.
resultsThe patient received 3 intramuscular injections of IL-7 at a dose of 10 μg/kg per week with no adverse effects. ALC peaked at 595 cells/μL, CD4+ T cells at 301 cells/μL, and CD8+ T cells at 34 cells/μL 3 weeks after completion of treatment. His lesions on MRI stabilized and neurologic examination mildly improved. JCV-specific T-cell responses measured by intracellular cytokine staining were not altered after treatment with IL-7 but there was a marked increase in regulatory T cells.
conclusionThis case further supports the investigational use of IL-7 in patients who develop PML in the setting of ICL. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with ICL and PML, IL-7 improves PML-related-outcomes. The study is rated Class IV because it is a case report.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.